110311-27-8

Basic information

• Product Name: Sulofenur
• Synonyms: Sulofenur;1-(p-Chlorophenyl)-3-(5-indanylsulfonyl)urea;1-(Indan-5-ylsulfonyl)-3-(4-chlorophenyl)urea;LY-186641
• CAS NO: 110311-27-8
• Molecular Formula: C₁₆H₁₅ClN₂O₃S
• Molecular Weight: 350.824
• Mol File: 110311-27-8.mol
• Article Data: 6

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.449g/cm³
• Refractive Index: 1.656
• CAS DataBase Reference: Sulofenur(CAS DataBase Reference)
• NIST Chemistry Reference: Sulofenur(110311-27-8)
• EPA Substance Registry System: Sulofenur(110311-27-8)

Safety Data

• Hazardous Substances Data: 110311-27-8(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 110311-27-8 differently. You can refer to the following data:
1. Antineoplastic.
2. Sulofenur can be used for preventing or treating cancer and autoimmune disorders, where it can be used as conjoint therapy for immunomodulation.

InChI:InChI=1/C16H15ClN2O3S/c17-13-5-7-14(8-6-13)18-16(20)19-23(21,22)15-9-4-11-2-1-3-12(11)10-15/h4-10H,1-3H2,(H2,18,19,20)

Upstream product

• 122-01-0 4-chloro-benzoyl chloride 
• 74-11-3 para-chlorobenzoic acid 
• 52205-86-4 N-(5-indansulfonyl)carbamate 
• 106-47-8 4-chloro-aniline 
• 52405-96-6 2,3-dihydro5-indenylsulfonylisocyanate 
• 35203-93-1 2,3-dihydro-5-indenylsulfonamide 
• 104-12-1 p-chlorphenylisocyanate 

Related news

Studies on the mechanism of Sulofenur (cas 110311-27-8) and LY295501 toxicity: effect on the regulation of cytosolic calcium in relation to cytotoxicity in normal and tumorigenic rat kidney cell lines08/12/2019

Treatment of NRK-52E (normal) and H/1.2-NRK-52E (Harvey-ras transfected NRK-52E) rat kidney epithelial-like cells with two Eli Lilly antitumor compounds, sulofenur and LY295501 (15.6μM–1000μM) resulted in concentration- and time-dependent cell killing. Cytosolic Ca2+ became elevated in both c...detailed

A 40-week male fertility study of the anticancer agent Sulofenur (cas 110311-27-8) (LY186641) administered orally to rats08/11/2019

Sulofenur was evaluated for fertility effects on rats. Five-week old male rats (20/group) received 0, 5, 30, or 60 mg Sulofenur/kg/day for 14 weeks. Fertility was evaluated five times. Treated males were mated with untreated females at 10 weeks. Half the males from each group were necropsied aft...detailed

H-ras transfection of the rat kidney cell line NRK-52E results in increased induction of c-fos, c-jun and hsp70 following Sulofenur (cas 110311-27-8) treatment08/10/2019

The effect of the antineoplastic drug sulofenur on the induction of the immediate-early genes (IEG) c-fos and c-jun and the stress gene hsp70 was compared in the rat kidney epithelial-like cell line NRK-52E and a derivative H-ras-transfected (H/1.2NRK-52E) cell line. Fold induction for each gene...detailed

Sulofenur (cas 110311-27-8) cytotoxicity and changes in cytosolic calcium and mitochondrial membrane potential in human colon adenocarcinoma cell lines08/09/2019

Sulofenur treatment (12.5 μM-1 mM) of colon adenocarcinoma cell lines resulted in dose- and time-dependent cell killing. LYc5 cells were viable longer than GC3c1, cells. Each concentration resulted in elevation of cytosolic calcium [Ca2+]i) for both cell lines. At lower doses, elevation was del...detailed

Pharmacokinetics of the Anticancer Agent Sulofenur (cas 110311-27-8) in Mice, Rats, Monkeys, and Dogs08/08/2019

The absorption and pharmacokinetics of sulofenur [N-(in- dan-5-sulfonyl)-N-(4-chlorophenyl)urea, LY186641] and its major metabolites were examined in mice, rats, monkeys, and dogs. The compound is a diarylsulfonylurea currently being evaluated as an oncolytic agent in phase I and II trials. In a...detailed

Relevant articles and documents

Sulfonylureas as Concomitant Insulin Secretagogues and NLRP3 Inflammasome Inhibitors

Insulin-secretory sulfonylureas are widely used, cost-effective treatments for type 2 diabetes (T2D). However, pancreatic β-cells are continually depleted as T2D progresses, thereby rendering the sulfonylurea drug class ineffective in controlling glycaemia. Dysregulation of the innate immune system via activation of the NLRP3 inflammasome, and the consequent production of interleukin-1β, has been linked to pancreatic β-cell death and multiple inflammatory complications of T2D disease. One proposed strategy for treating T2D is the use of sulfonylurea insulin secretagogues that are also NLRP3 inhibitors. We report the synthesis and biological evaluation of nine sulfonylureas that inhibit NLRP3 activation in murine bone-marrow- derived macrophages in a potent, dose-dependent manner. Six of these compounds inhibited NLRP3 at nanomolar concentrations and can also stimulate insulin secretion from a murine pancreatic cell line (MIN6). These novel compounds possess unprecedented dual modes of action, paving the way for a new generation of sulfonylureas that may be useful as therapeutic candidates and/or tool compounds in T2D and its associated inflammatory complications.

Diarylsulfonylureas for use in treating secretory diarrhea

This invention provides methods of treating secretory diarrhea or cystic fibrosis in a mammal which comprises administering to a mammal in need thereof an effective amount of diarylsulfonylurea. This invention also describes specific diarylsulfonylureas f

Anti-tumor method and compounds

This invention provides certain N-[(phenyl)amino]carbonyl-bicyclicsulfonamide sulfonamide derivatives, their pharmaceutical formulations, and their use in the treatment of susceptible neoplasms in mammals.